Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antifungal medication
|
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J02AA01
|
| gptkbp:brand |
gptkb:amphotericin_B
|
| gptkbp:chemicalClass |
polyene antifungal
|
| gptkbp:contraindication |
hypersensitivity to amphotericin B
|
| gptkbp:discoveredIn |
1950s
|
| gptkbp:eliminationHalfLife |
15 days
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fungizone
|
| gptkbp:indication |
gptkb:histoplasmosis
candidiasis aspergillosis blastomycosis coccidioidomycosis cryptococcal meningitis systemic mycoses |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:metabolism |
unknown
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:producedBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
fever chills hypokalemia nephrotoxicity |
| gptkbp:usedFor |
treatment of fungal infections
|
| gptkbp:bfsParent |
gptkb:amphotericin_B
|
| gptkbp:bfsLayer |
6
|